Correnti, Colin E.
Laszlo, George S.
de van der Schueren, Willem J.
Godwin, Colin D.
Bandaranayake, Ashok
Busch, Melanie A.
Gudgeon, Chelsea J.
Bates, Olivia M.
Olson, James M.
Mehlin, Christopher
Walter, Roland B. http://orcid.org/0000-0002-9268-3341
Article History
Received: 12 November 2017
Revised: 5 December 2017
Accepted: 18 December 2017
First Online: 31 January 2018
Compliance with ethical standards
:
: RBW has received laboratory research grants and/or clinical trial support from Amgen Inc., Amphivena Therapeutics, Inc., Covagen AG, Aptevo Therapeutics, Inc., and Seattle Genetics, Inc.; has ownership interests with Amphivena Therapeutics, Inc.; and is (or has been) a consultant to Amphivena Therapeutics, Inc., Covagen AG, Emergent Biosolutions, Inc. (now Aptevo Therapeutics, Inc.), Pfizer, Inc., and Seattle Genetics, Inc. The remaining authors declare that they have no conflict of interest.